Drugs / BI 905681
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04147247 | Dec 2019 → May 2021 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 905681 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04147247 ↗ |
| Route | Intravenous | “BI 905681 given as an intravenous infusion” NCT04147247 ↗ |